ConserV is a late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. We have a pipeline of eight vaccines in pre-clinical and clinical development including broad-spectrum influenza*, broad-spectrum coronavirus, mosquito-borne diseases*, HIV, Hepatitis C, Hepatitis B, Rotavirus and Chagas. ConserV’s USP is the identification of antigens consisting of conserved regions of viral proteins containing a high number of REACTIVE T-cell epitopes with extensive HLA coverage. *Sub-licensed to Imutex Limited, a 51% owned subsidiary. hVIVO Services Limited own 49% of Imutex.
| Website | http://conservbio.com |
| Employees | 3 (3 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology |
| Keywords | Biopharma, Vaccine Development, Clinical Trials, Infectious Disease Vaccines, Vaccine Research, Emerging Infectious Diseases, Vaccine Technology, Immunology Research, Pharmaceutical Research, Biotechnology, Drug Development, Life Sciences, Therapeutics, Vaccines, Public Health |
| Competitors | Codexis, Inc., Amyris, Geno, Novozymes, Solugen, Zymergen, Inc., PureTech Health, Metabolex , Inc., Tradewater Power & Energy Systems Inc, Universal Biologics +24 more (view full list) |
Looking for a particular ConserV Bioscience employee's phone or email?
ConserV Bioscience Questions
Kimbell Duncan is the CEO of ConserV Bioscience.
3 people are employed at ConserV Bioscience.
Top ConserV Bioscience Employees
